Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

NCT03534635 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Interventions

DRUG: Pembrolizumab
DRUG: Pembrolizumab - additional treatment

Sponsor

Centre Hospitalier Universitaire Vaudois